Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVA: Neoadjuvant FEC 100 followed by Taxotere + Vectibix in operable HR- and HER2-negative breast cancer
2009-012853-39Phase 2Active
- Sponsor
- Centre Jean Perrin
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in Infiltrating Ductal Carcinoma (IDC), sponsored by Centre Jean Perrin. Primary endpoint: Complete histological response (Chevallier’s classification, breast and nodes). Started Jul 2009; status: active.
02
Drugs
panitumumab
03
Conditions
Infiltrating Ductal Carcinoma (IDC)
Beyond the preview
Go deeper on 2009-012853-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012853-39.